
|Videos|June 2, 2015
Adding Palbociclib Delays Progression in HR-Positive Breast Cancer
Author(s)Nicholas C. Turner, MD
In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.
Advertisement
In this video, Nicholas C. Turner, MD, of Royal Marsden Hospital and the Cancer Research Institute in London, discusses the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor (HR)-positive HER2-negative breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Low-Dose CT Screening Reduces Lung Cancer–Specific Mortality
2
FDA Approves Companion Diagnostic for Pembrolizumab in Esophageal/GEJ Carcinoma
3
Frontline IO-Combos, Next-Generation ADCs: Evolutions in Endometrial Cancer
4
Durvalumab/SBRT May Limit Tumor Progression in Early-Stage NSCLC
5






















































